Beta Blockers

# Beta blockers ## Overview - **Classification**: Beta-adrenergic receptor antagonists (beta-blockers). - **Mechanism**: Competitively block beta-1 and/or beta-2 adrenergic receptors. This reduces heart rate, myocardial contractility, and blood pressure. Some also have intrinsic sympathomimetic activity (ISA) or alpha-blocking properties. ## Primary Indications 1. **Hypertension** - Management of high blood pressure. 2. **Angina Pectoris** - Prophylaxis against chest pain. 3. **Heart Failure** - Chronic stable heart failure (specific agents, e.g., metoprolol succinate, carvedilol). 4. **Myocardial Infarction** - Reduce mortality post-MI and prevent recurrence. 5. **Arrhythmias** - Rate control for supraventricular tachycardias (e.g., atrial fibrillation). 6. **Migraine Prophylaxis** - Prevention of migraine headaches. 7. **Essential Tremor** - Symptomatic relief of essential tremor. ## Adult Dosing ### Representative Standard Dosing Examples **Metoprolol Tartrate (Immediate Release)** - **Indication**: Hypertension, Angina - **Dose**: **50-200 mg** - **Frequency**: Once or twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **400 mg/day** - **Indication**: Post Myocardial Infarction - **Dose**: **25-50 mg** - **Frequency**: Every 6-12 hours (Q6-12h) - **Route**: Oral (PO) **Metoprolol Succinate (Extended Release)** - **Indication**: Hypertension, Angina - **Dose**: **25-100 mg** - **Frequency**: Once daily (QD) - **Route**: Oral (PO) - **Maximum**: **400 mg/day** - **Indication**: Heart Failure (NYHA Class II-IV) - **Dose**: Initiate at **12.5-25 mg** - **Frequency**: Once daily (QD) - **Route**: Oral (PO) - **Titration**: Slowly titrate every 2 weeks to target **200 mg/day** as tolerated. **Propranolol (Immediate Release)** - **Indication**: Hypertension, Angina, Migraine Prophylaxis, Essential Tremor - **Dose**: Initiate **20-40 mg** - **Frequency**: Two to four times daily (BID-QID) - **Route**: Oral (PO) - **Titration**: Adjust dose based on response. - **Maximum**: **320 mg/day** for hypertension, up to **240 mg/day** for migraine. ### Dose Adjustments - **Renal Impairment**: Generally **no specific dose adjustment** needed for most beta-blockers. Monitor for adverse effects. - **Hepatic Impairment**: - Use with **caution**. Hepatically metabolized beta-blockers (e.g., propranolol, metoprolol) may require **dose reduction** (e.g., **25-50%** reduction) in severe impairment. - Monitor for increased plasma concentrations and adverse effects. - **Elderly Patients**: - Start with **lower doses** (e.g., **50% of adult dose**) and titrate slowly. - Increased sensitivity to effects, higher risk of bradycardia and hypotension. ## Pediatric Dosing (Example: Propranolol) ### Neonates (0-28 days) - **Indication**: Hypertension (off-label), Tachyarrhythmias (off-label) - **Dose**: Start **0.25-0.5 mg/kg/dose** - **Frequency**: Every 6-12 hours (Q6-12h) - **Route**: Oral (PO) - **Maximum**: **1 mg/kg/dose** (single); **2 mg/kg/day** (total daily dose). - **Special Notes**: Careful monitoring for bradycardia, hypotension, and hypoglycemia. Use oral solution. ### Infants (1-12 months) - **Indication**: Infantile Hemangioma, Hypertension, Arrhythmias - **Dose (Hypertension/Arrhythmias)**: Start **0.5-1 mg/kg/dose** - **Frequency**: Every 6-8 hours (Q6-8h) - **Route**: Oral (PO) - **Maximum**: **5 mg/kg/day** (total daily dose). - **Dose (Infantile Hemangioma)**: Initiate **0.6 mg/kg/day** in 2 divided doses for 1 week. Increase to **1.1 mg/kg/day** for 1 week. Target **1.7 mg/kg/day**. - **Frequency**: Twice daily (BID) for hemangioma. - **Special Notes**: Monitor HR, BP, and blood glucose. Administer with food. ### Children (1-12 years) - **Indication**: Hypertension, Migraine Prophylaxis, Arrhythmias - **Dose (Hypertension)**: Initiate **0.5-1 mg/kg/day** - **Frequency**: Divided BID-QID - **Route**: Oral (PO) - **Maximum**: **2-4 mg/kg/day** or **60 mg/day** (whichever is less). - **Dose (Migraine Prophylaxis)**: **10-20 mg** - **Frequency**: Two to three times daily (BID-TID) - **Maximum**: **160 mg/day**. ### Adolescents (13-18 years) - **Indication**: Hypertension, Migraine Prophylaxis, Arrhythmias, Essential Tremor - **Dose**: Generally approach adult dosing. - **Frequency**: As per adult guidelines. - **Route**: Oral (PO) - **Maximum**: **320 mg/day** (hypertension); **240 mg/day** (migraine prophylaxis). ## Safety Information ### Contraindications - **Absolute**: - Symptomatic bradycardia (HR < 45-50 bpm). - Second- or third-degree AV block without a pacemaker. - Cardiogenic shock or decompensated heart failure requiring inotropes. - Severe uncontrolled asthma or severe COPD exacerbation (especially non-selective agents). - **Relative**: - Well-controlled asthma/COPD (use beta-1 selective agents with caution). - Diabetes mellitus (may mask hypoglycemia symptoms). - Peripheral vascular disease or Raynaud's phenomenon. ### Common Adverse Effects - **Very Common (>10%)**: Bradycardia, fatigue, dizziness, hypotension. - **Common (1-10%)**: Nausea, diarrhea, bronchospasm (non-selective), sexual dysfunction, cold extremities, insomnia. - **Serious but Rare**: Exacerbation of heart failure, severe bronchospasm, complete AV block, masking of hypoglycemia, acute renal failure (rare), severe depression. ### Key Drug Interactions - **Non-dihydropyridine Calcium Channel Blockers (e.g., Verapamil, Diltiazem)**: - **Effect**: Additive negative chronotropic and inotropic effects. Risk of severe bradycardia, AV block, and hypotension. - **Monitoring**: Close monitoring of HR, BP, ECG. Avoid concomitant use if possible. - **Digoxin**: - **Effect**: Additive bradycardia. - **Monitoring**: Monitor heart rate. - **Antiarrhythmics (e.g., Amiodarone)**: - **Effect**: Increased risk of bradycardia and AV block. - **Monitoring**: ECG and HR monitoring. - **NSAIDs**: - **Effect**: May reduce the antihypertensive effects of beta-blockers. - **Clinical Significance**: Monitor blood pressure. - **Alpha-1 Blockers (e.g., Prazosin, Doxazosin)**: - **Effect**: Increased risk of orthostatic hypotension. - **Monitoring**: Advise patients to rise slowly. ## Monitoring & Follow-up - **Before Treatment**: - Measure heart rate (HR) and blood pressure (BP). - Obtain an electrocardiogram (ECG) to assess PR interval and rhythm. - Assess for history of asthma/COPD, diabetes, or heart failure. - **During Treatment**: - **BP and HR**: Routinely monitor (e.g., at each visit). - **Clinical Status**: Assess for signs of heart failure exacerbation (dyspnea, edema), bronchospasm, or new onset arrhythmia. - **Glucose**: Monitor blood glucose levels more closely in diabetic patients. - **Renal/Hepatic function**: Periodically in patients with pre-existing impairment. - **Clinical Signs**: Patients should report dizziness, excessive fatigue, shortness of breath, significant swelling in legs/ankles, or chest pain. ## Clinical Pearls - 💡 **Abrupt Withdrawal**: Do not discontinue beta-blockers abruptly, especially in patients with ischemic heart disease, as it can precipitate angina, MI, or arrhythmias. Taper dose gradually over **1-2 weeks**. - 💡 **Administration with Food**: Some beta-blockers (e.g., metoprolol, carvedilol) may have increased bioavailability or reduced orthostatic hypotension when taken with food. Advise consistency. - 💡 **Masked Hypoglycemia**: Beta-blockers, particularly non-selective agents, can mask symptoms of hypoglycemia (e.g., tremors, palpitations) in diabetic patients. Sweating is usually not masked. - 💡 **Selectivity**: Beta-1 selective agents (e.g., metoprolol, atenolol, bisoprolol) are generally preferred in patients with lung disease or diabetes, but should still be used with caution. At high doses, selectivity is lost. - 💡 **Patient Education**: Advise patients to monitor their pulse and blood pressure at home, if possible, and to report symptoms of bradycardia or hypotension. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing or making treatment decisions.